title: BCL10 expression in ocular adnexal lymphomas.
abstract: OBJECTIVE
  To study BCL10 expression in ocular adnexal lymphoma in the US population and its association with clinical outcomes.
  
  
  METHODS
  Institutional, retrospective study.
  
  
  METHODS
  Immunohistochemistry was performed with antibody against BCL10 on two tissue microarray blocks that were constructed with paraffin-embedded tissues from the same cohort of 48 patients with ocular adnexal lymphomas. The main outcomes that were measured include extraorbital involvement, recurrence rate, and time to recurrence. The median length of the follow-up period was 40 months.
  
  
  RESULTS
  Aberrant BCL10 expression (nuclear [moderate intensity] and cytoplasmic [weak to moderate intensity] staining) was observed in 10 of 33 cases (30.3%) of mucosa-associated lymphoid tissue (MALT) lymphoma, in 4 of 10 cases (40%) of follicular lymphoma (grade 1, 9 cases; grade 2, 1 case), in 0 of 2 cases of diffused large B-cell lymphoma, in 0 of 1 case of chronic lymphocytic leukemia/small lymphocytic lymphoma and in 1 of 1 case (100%) of mantle cell lymphoma. There were no differences in clinical parameters at examination (ie, average age, gender, site of occurrence, laterality, extraorbital involvement at diagnosis), recurrence rate, and time to recurrence for patients (MALT lymphoma or follicular lymphoma) with or without aberrant nuclear BCL10 expression.
  
  
  CONCLUSIONS
  Aberrant BCL10 expression can occur in other types of ocular adnexal lymphomas besides MALT lymphoma. Ocular adnexal MALT lymphoma may have slightly lower frequency of aberrant BCL10 expression than gastric/pulmonary MALT lymphomas that have been reported in the literature. Furthermore, aberrant BCL10 nuclear expression in ocular adnexal lymphoma does not seem to correlate with clinical outcome. Further studies that include a larger number of cases and longer follow-up period are needed to confirm our observation.
authors.affiliation: Department of Pathology, Baylor College of Medicine, Houston, Texas, USA.
authors.forename: Choladda
authors.initials: C
authors.lastname: Vejabhuti
authors.forename: Gerald J
authors.initials: GJ
authors.lastname: Harris
authors.forename: Beth A
authors.initials: BA
authors.lastname: Erickson
authors.forename: Ha
authors.initials: H
authors.lastname: Nishino
authors.forename: Patricia
authors.initials: P
authors.lastname: Chevez-Barrios
authors.forename: Chung-Che
authors.initials: CC
authors.lastname: Chang
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000074018:B-Cell CLL-Lymphoma 10 Protein; D003230:Conjunctival Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D005134:Eye Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D007766:Lacrimal Apparatus Diseases / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D008223:Lymphoma / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000074018:B-Cell CLL-Lymphoma 10 Protein; C118591:BCL10 protein, human